AstraZeneca Names Chair-DesignateBy
AstraZeneca has named Michel Demaré, currently a Non-Executive Director and Member of the company’s Board, as Chair-Designate following the decision by Leif Johansson, the company’s current Chairman, to retire at the conclusion of the company’s annual general meeting in April 2023. Demaré’s appointment as Chair-designate will take effect immediately on Johansson’ retirement to allow for a managed handover period over the coming months (as reported on July 29, 2022).
Johansson was elected to AstraZeneca’s Board of Directors in April 2012 and has served as its Chairman since June 2012
Demaré was appointed to the Board of AstraZeneca in September 2019 as an independent Non-Executive Director and is Chair of the company’s Remuneration Committee and is a member of the Audit Committee and the Nomination and Governance Committee. He is also a Non-Executive Director of Vodafone Group, a multinational telecommunications company, and Louis Dreyfus Int’l Holdings, a holding company with interests in agricultural, food processing, and other areas. He is also Chairman of the IMD Business School based in Lausanne, Switzerland, and Chairman of Nomoko AG, a Zurich, Switzerland-based software and information technology company